Resources
Explore how healthcare organizations, researchers, and life sciences partners from our global community use TriNetX to turn real-world patient data into evidence that drives progress.
Reflecting on the discussions from this year’s International Society for Pharmacoepidemiology (ISPE) Annual Meeting and looking ahead to the future of the field, I’m struck by the steady but significant evolution pharmacoepidemiology is undergoing driven in large part by innovations in real-world data (RWD).
Many clinical data networks often focus on a single use-case or disease. By contrast, the TriNetX Dataworks-USA Network contains real-world clinical information that can be applied to multiple research questions and use cases.
To characterize the use of and factors associated with GLP-1 initiation among US adults undergoing bariatric surgery.
Sanofi UK, a leading pharmaceutical company, sought an innovative solution to address challenges in clinical trial recruitment and feasibility.
There has been a proliferation of large-scale electronic health record (EHR) data platforms that pool across multiple healthcare organizations
Discover how partnering with TriNetX will enable you to advance rare disease research.
In just a few years, real-world data (RWD) has evolved from an industry buzzword to a core driver of progress in drug development. What used to be experimental is now operational and increasingly essential. In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, more than three-quarters said their organizations are already applying RWD across some part of the drug development lifecycle. We’re clearly well beyond the pilot phase.
Pediatric obstructive sleep apnea (OSA) affects an estimated 1–3 % of children, corresponding to over 40 million cases globally.
Analysis reveals strategic opportunities for pharmaceutical leaders to close treatment gaps and accelerate breakthroughs in underserved rare disease communities.
TriNetX is compliant with the Health Insurance Portability and Accountability Act (HIPAA), the US federal law which protects the privacy and security of healthcare data. TriNetX is certified to the ISO 27001:2022 standard and maintains an Information Security Management System
Clostridioides difficile infection (CDI) is a major cause of infectious diarrhea in the inpatient and community setting
Dr. David Karp, Chief of the Division of Rheumatic Diseases at UT Southwestern Medical Center, leads research efforts in systemic lupus erythematosus (SLE), a rare and complex autoimmune condition that disproportionately affects women of color.
Upcoming Webinar
From Data to Evidence: A Framework for RWD Study Design & Causal Inference
Thursday, July 16 | 11am ET
Generating credible evidence from real-world data (RWD) requires more than access to data — it demands intentional alignment between the research question, study design, and data source. Yet even experienced teams fall into the trap of starting with the data and working backward, a shortcut that can undermine the trustworthiness of study findings.
Join TriNetX Chief Scientific Officer Jeffrey Brown, PhD, and Miguel Hernán, MD, PhD, ScD, Director of CAUSALab at Harvard, as they walk through a practical framework for designing rigorous RWD studies for causal inference. Attendees will leave with concrete tools for sequencing their research approach, evaluating data fitness, and applying sound decision-making to their own studies.
Join a global community of innovators. Discover how to turn real-world data into groundbreaking clinical insights.
Meet TriNetX at Events
Bridge the gap between raw data and patient care. Meet the team at flagship healthcare conferences across the globe, and learn how to leverage the TriNetX ecosystem to streamline trial timelines, improve site collaboration, and publish research that changes lives.
